MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
NeuBase Therapeutics Total Liabilities 2011-2026 | NBSE
Annual Total Liabilities NeuBase Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.5 M | 10.1 M | 3.15 M | 2.5 M | 725 K | 5.08 M | 4.48 M | 3.88 M | 5.27 M | 480 K | 1.09 M | 6.19 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 M | 480 K | 4.37 M |
Quarterly Total Liabilities NeuBase Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.48 M | 11.1 M | 7.01 M | 7.36 M | 9.5 M | 9.68 M | 10.6 M | 9.91 M | 10.1 M | 9.04 M | 10.1 M | 2.24 M | 3.15 M | 3.15 M | 3.15 M | 2.85 M | 2.5 M | 2.5 M | 2.5 M | 530 K | 291 K | 725 K | 597 K | 3.75 M | 5.08 M | 5.08 M | 5.08 M | 3.89 M | 4.48 M | 4.48 M | 4.48 M | 5.28 M | 3.88 M | 3.88 M | 3.88 M | 6.78 M | 5.27 M | 5.27 M | 5.27 M | 250 K | 480 K | 480 K | 480 K | 2.38 M | 1.09 M | 1.09 M | 1.09 M | 5.53 M | 6.19 M | 6.19 M | 6.19 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.1 M | 250 K | 4.62 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 4.55 | -0.66 % | $ 10.9 B |  Australia |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Compugen Ltd.
CGEN
|
18.5 M | $ 2.59 | -5.31 % | $ 242 M |  Israel |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
4.9 M | $ 0.91 | 3.25 % | $ 6.69 M | China |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 22.57 | -0.44 % | $ 3.74 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Evogene Ltd.
EVGN
|
8.07 M | $ 0.78 | -0.66 % | $ 27.9 M | Israel |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
35.1 M | $ 6.33 | -5.52 % | $ 181 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Galapagos NV
GLPG
|
171 M | $ 27.94 | -1.69 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
2.02 B | $ 26.19 | -2.24 % | $ 16 B |  Danmark |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 100.7 | -1.33 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
383 M | $ 23.2 | -2.08 % | $ 1.56 B | USA |
 |
Innate Pharma S.A.
IPHA
|
151 M | $ 1.45 | 3.57 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
226 M | $ 4.93 | -1.5 % | $ 138 M | France |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.06 | -0.73 % | $ 434 M | USA |
 |
Jaguar Health
JAGX
|
57 M | $ 0.23 | -5.44 % | $ 536 K | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 22.63 | -2.86 % | $ 2.88 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
338 M | $ 26.73 | 38.9 % | $ 1.44 B | Britain |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.42 | -4.39 % | $ 378 M | Britain |
 |
Kamada Ltd.
KMDA
|
32 M | $ 8.14 | -0.09 % | $ 260 M | Israel |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.95 | 1.37 % | $ 4.86 M | Israel |